CUSTOM BIOMARKER DEVELOPMENT

 

 

We utilize our proprietary single cell CTC platform to develop blood based biomarkers for solid tumor indications with our pharma partners.  Measurability is determined by analyzing a patient cohort for:

  1. CTC prevalence
  2. CTC phenotypes/genotypes
  3. Heterogeneity of phenotypes/genotypes
  4. Associations between specific CTC subtypes and therapeutic responses at decision points and throughout care

These ‘signatures’ can then be assessed in larger patient cohorts to help drug makers in find larger treatable patient populations for novel therapeutic trials.

 
The flow diagram (left panel) describes the stepwise biomarker development process and specific tools employed to develop a custom biomarker utilizing Epic Sciences’ proprietary CTC platform. Key questions to be addressed by translational researchers (middle) and the tools used (right) are shown in the figure.

Contact us to discuss custom biomarker development.

UP TO DATE WITH EPIC SCIENCES

All of Epic Sciences’ offerings can be included in your companion diagnostic assay to ensure the right treatment for the right patient at the right time. Request more information on CDx capabilities here: info@epicsciences.com